TY - JOUR
T1 - Efficacy of On-Demand Asimadoline, a Peripheral κ-Opioid Agonist, in Females With Irritable Bowel Syndrome
AU - Szarka, Lawrence A.
AU - Camilleri, Michael
AU - Burton, Duane
AU - Fox, Jean C.
AU - McKinzie, Sanna
AU - Stanislav, Timothy
AU - Simonson, Julie
AU - Sullivan, Nancy
AU - Zinsmeister, Alan R.
PY - 2007/11
Y1 - 2007/11
N2 - Background & Aims: In experimental animal models of irritable bowel syndrome (IBS) and human studies, peripheral κ opioid agonists have been shown to decrease sensation to colonic distention. The aim of this study was to compare the effects of the κ opioid agonist, asimadoline, and placebo on episodes of abdominal pain in patients with IBS. Methods: After a 2-week run-in period, 100 patients with IBS were randomized (3:2 ratio) to receive asimadoline, up to 1 mg 4 times daily, or placebo for 4 weeks in a double-blind study. Pain was scored by daily diary using a 100-mm visual analogue scale. During pain episodes, patients recorded the pain severity, took study medication, and recorded their pain score 2 hours later. The primary end point was the average reduction in pain severity 2 hours after treatment. Results: The average pain reduction 2 hours posttreatment was not significantly different between the groups. Post hoc analyses suggest asimadoline was effective in mixed IBS (P = .003, unadjusted), but may be worse in diarrhea-predominant IBS (P = .065 unadjusted). The anxiety score was reduced modestly by asimadoline (P = .053). No significant adverse effects were noted. Conclusions: An on-demand dosing schedule of asimadoline was not effective in reducing severity of abdominal pain in IBS. Further studies in visceral pain and IBS appear warranted.
AB - Background & Aims: In experimental animal models of irritable bowel syndrome (IBS) and human studies, peripheral κ opioid agonists have been shown to decrease sensation to colonic distention. The aim of this study was to compare the effects of the κ opioid agonist, asimadoline, and placebo on episodes of abdominal pain in patients with IBS. Methods: After a 2-week run-in period, 100 patients with IBS were randomized (3:2 ratio) to receive asimadoline, up to 1 mg 4 times daily, or placebo for 4 weeks in a double-blind study. Pain was scored by daily diary using a 100-mm visual analogue scale. During pain episodes, patients recorded the pain severity, took study medication, and recorded their pain score 2 hours later. The primary end point was the average reduction in pain severity 2 hours after treatment. Results: The average pain reduction 2 hours posttreatment was not significantly different between the groups. Post hoc analyses suggest asimadoline was effective in mixed IBS (P = .003, unadjusted), but may be worse in diarrhea-predominant IBS (P = .065 unadjusted). The anxiety score was reduced modestly by asimadoline (P = .053). No significant adverse effects were noted. Conclusions: An on-demand dosing schedule of asimadoline was not effective in reducing severity of abdominal pain in IBS. Further studies in visceral pain and IBS appear warranted.
UR - http://www.scopus.com/inward/record.url?scp=35548931920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35548931920&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2007.07.011
DO - 10.1016/j.cgh.2007.07.011
M3 - Article
C2 - 17900994
AN - SCOPUS:35548931920
SN - 1542-3565
VL - 5
SP - 1268
EP - 1275
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 11
ER -